Better Buy: Bellicum Pharmaceuticals, Inc. vs. Celldex Therapeutics

Image source: Getty Images.

Continue Reading Below

Investors in cellular therapy developerBellicum Pharmaceuticals, Inc. (NASDAQ: BLCM)and targeted cancer treatment specialistCelldex Therapeutics(NASDAQ: CLDX) watched in horror this spring as both biotech stocks lost over 50% of their value. Bellicum has recovered somewhat but is still down 22% year to date. For Celldex, a clinical upset in March continues pushing the stock about 70% lower than its value at the beginning of the year.

Both companies are advancing unique therapies while burning through cash, and neither has any products to sell yet, but the similarities end there. Let's look closer at their pipelines in light of the recent price divergence to see which is a better buy right now.

The case for Bellicum Pharmaceuticals


<3>More From Fool.com

Continue Reading Below